Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis - United States
doi 10.1177/1076029618825309
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Acquired Thrombotic Thrombocytopenic Purpura

2020English

Long-Term Neuropsychological Sequelae, Emotional Wellbeing and Quality of Life in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Haematologica
Hematology
2019English

Blue Nose Syndrome in Acquired Thrombotic Thrombocytopenic Purpura

Intensive Care Medicine
Critical CareIntensive Care Medicine
2017English

Thrombotic Thrombocytopenic Purpura

American Journal of Medicine
Medicine
1959English

Thrombotic Thrombocytopenic Purpura

Laboratory Medicine
BiochemistryClinical Biochemistry
1988English

Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders

Journal of Clinical Apheresis
MedicineHematology
2006English

Increased Morbidity During Long-Term Follow-Up of Survivors of Thrombotic Thrombocytopenic Purpura

American Journal of Hematology
Hematology
2015English

Rituximab-Induced Acute and Delayed Serum Sickness in Thrombotic Thrombocytopenic Purpura: The Role of Anti-Rituximab Antibodies

British Journal of Haematology
Hematology
2018English

Preventable Deaths During Initial Episodes of Acquired Thrombotic Thrombocytopenic Purpura: Past and Future

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy